| |
The scientific community universally recognizes peer-reviewed literature as the foundation of credible and reproducible research. However, its exponential growth presents a significant challenge for R&D teams in biotech and pharma companies. Learn how to leverage AI to ensure that today’s advancements in drug discovery, clinical trials and regulatory processes are based on data that is up-to-date, validated and meaningful. Download now. 
|
|
Today’s Big NewsJul 15, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By Darren Incorvaia The Department of Health and Human Services (HHS) is laying off certain employees that were notified months ago of the reduction in force (RIF) after the Supreme Court lifted a district court order blocking the layoffs, an agency spokesperson confirmed to Fierce Biotech. |
|
|
|
By Angus Liu Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ongoing oncology partnerships with Merck & Co. and AstraZeneca. |
By Conor Hale Since Bergman was named CEO in 1989, the medical, surgical and dental supply maker has seen its annual revenues grow from $225 million to $12.7 billion in 2024. |
By Kevin Dunleavy GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to patients in poorer nations for HIV treatment. |
|
Wednesday, July 23, 2025 | 2pm ET / 11am PT The development of radiopharmaceuticals is transforming oncology. Designing successful clinical trials in this space, requires a precise balance of insight, efficiency, and strategy. Join our expert panel to explore the imaging strategies, trial design principles, and regulatory alignment considerations you need to know about. Register now. 
|
|
By Andrea Park As Miami-based Veru continues development of its enobosarm to prevent muscle wasting in patients being treated for obesity, among other conditions, the biopharma has conducted a survey showing that the side effect looms large in the minds of GLP-1 users. |
By Eric Sagonowsky As GSK's Blenrep makes its return to markets around the world, the company has big expectations for the antibody-drug conjugate. But FDA reviewers are taking a close look at safety data from two phase 3 trials. |
By Gabrielle Masson Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. |
By Conor Hale Zimmer Biomet inked a $177 million deal to purchase Monogram Technologies, developer of a hands-free robotic surgery system for performing total knee replacements. |
By Zoey Becker Along with the CEO transition announcement, the company disclosed preliminary financial results showing a 4% sales slide during the second quarter. |
By James Waldron Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a $555 million biobucks pact with Alzheimer’s-focused Acumen Pharmaceuticals. |
By Fraiser Kansteiner With transatlantic expansions nearing completion and a new acquisition in the books, PCI Pharma Services has secured a confidence vote—and capital to go with it—from a slate of private equity heavy hitters, including new backer Bain Capital. |
Fierce podcasts Don’t miss an episode |
| Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
|
|---|
|
|
|
QPS delivers global RWE solutions to support regulatory and drug development goals. With access to diverse data sources and deep regulatory expertise, QPS transforms real-world data into actionable insights. +(2)+(2)+(1)+(1)+(1).png)
|
|
Whitepaper This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Sheraton Philadelphia Downtown |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
